298 related articles for article (PubMed ID: 16269515)
1. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
Friedrichsen BN; Galsgaard ED; Nielsen JH; Møldrup A
Mol Endocrinol; 2001 Jan; 15(1):136-48. PubMed ID: 11145745
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
5. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways.
Um M; Lodish HF
J Biol Chem; 2006 Mar; 281(9):5648-56. PubMed ID: 16407271
[TBL] [Abstract][Full Text] [Related]
6. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.
Langenheim JF; Chen WY
J Endocrinol; 2009 Dec; 203(3):375-87. PubMed ID: 19770179
[TBL] [Abstract][Full Text] [Related]
7. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
9. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
10. Human growth hormone: 45-kDa isoform with extraordinarily stable interchain disulfide links has attenuated receptor-binding and cell-proliferative activities.
Bustamante JJ; Grigorian AL; Muñoz J; Aguilar RM; Treviño LR; Martinez AO; Haro LS
Growth Horm IGF Res; 2010 Aug; 20(4):298-304. PubMed ID: 20472479
[TBL] [Abstract][Full Text] [Related]
11. Stoichiometric structure-function analysis of the prolactin receptor signaling domain by receptor chimeras.
Chang WP; Ye Y; Clevenger CV
Mol Cell Biol; 1998 Feb; 18(2):896-905. PubMed ID: 9447986
[TBL] [Abstract][Full Text] [Related]
12. Alpha
Castillo LF; Rivero EM; Goffin V; Lüthy IA
Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).
Zhang Y; Gc S; Patel SB; Liu Y; Paterson AJ; Kappes JC; Jiang J; Frank SJ
Mol Cell Endocrinol; 2019 Jul; 492():110445. PubMed ID: 31100495
[TBL] [Abstract][Full Text] [Related]
14. Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites.
Kinet S; Bernichtein S; Kelly PA; Martial JA; Goffin V
J Biol Chem; 1999 Sep; 274(37):26033-43. PubMed ID: 10473550
[TBL] [Abstract][Full Text] [Related]
15. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
16. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
18. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
19. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.
Bole-Feysot C; Goffin V; Edery M; Binart N; Kelly PA
Endocr Rev; 1998 Jun; 19(3):225-68. PubMed ID: 9626554
[TBL] [Abstract][Full Text] [Related]
20. Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering.
Yang N; Langenheim JF; Wang X; Jiang J; Chen WY; Frank SJ
Mol Endocrinol; 2008 Apr; 22(4):978-88. PubMed ID: 18096690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]